4.2 Article

Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 24, Issue 6, Pages 1111-1118

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2018.01.029

Keywords

Hematopoietic cell transplantation; Survivorship; Patient-centered outcomes

Funding

  1. Patient-Centered Outcomes Research Institute Eugene Washington Engagement Award [PCORI EAIN-2956]

Ask authors/readers for more resources

The goal of patient-centered outcomes research (PCOR) is to help patients and those who care for them make informed decisions about healthcare. However, the clinical research enterprise has not involved patients, caregivers, and other nonproviders routinely in the process of prioritizing, designing, and conducting research in hematopoietic cell transplantation (HCT). To address this need the National Marrow Donor Program/Be The Match engaged patients, caregivers, researchers, and other key stakeholders in a 2-year project with the goal of setting a PCOR agenda for the HCT community. Through a collaborative process we identified 6 major areas of interest: (1) patient, caregiver, and family education and support; (2) emotional, cognitive, and social health; (3) physical health and fatigue; (4) sexual health and relationships; (5) financial burden; and (6) models of survivorship care delivery. We then organized into multistakeholder working groups to identify gaps in knowledge and make priority recommendations for critical research to fill those gaps. Gaps varied by working group, but all noted that a historical lack of consistency in measures use and patient populations made it difficult to compare outcomes across studies and urged investigators to incorporate uniform measures and homogenous patient groups in future research. Some groups advised that additional pre-emptory work is needed before conducting prospective interventional trials, whereas others were ready to proceed with comparative clinical effectiveness research studies. This report presents the results of this major initiative and makes recommendations by working group on priority questions for PCOR in HCT. (C) 2018 American Society for Blood and Marrow Transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma

Yazeed Sawalha, Tomas Radivoyevitch, Xuefei Jia, Katherine Tullio, Robert M. Dean, Brad Pohlman, Brian T. Hill, Matt Kalaycio, Navneet S. Majhail, Deepa Jagadeesh

Summary: Younger patients with private insurance and receiving treatment at academic facilities are more likely to undergo autologous stem cell transplantation for mantle cell lymphoma, which is associated with improved survival rates.

LEUKEMIA & LYMPHOMA (2022)

Letter Biophysics

Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation

Pranay Hegde, Lisa Rybicki, Sheila Serafino, Christina Ferraro, Matt Kalaycio, Ronald Sobecks, Aaron T. Gerds, Sharon Caroniti, Donna Corrigan, Kayla Giannetti, Jamie Elberson, Brittany Hodgeman, Jamie Starn, Jane Dabney, Linda McLellan, Navneet S. Majhail, Betty K. Hamilton

BONE MARROW TRANSPLANTATION (2022)

Letter Biophysics

Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation

Julia H. Joo, Sanghee Hong, Lisa A. Rybicki, Betty K. Hamilton, Navneet S. Majhail

BONE MARROW TRANSPLANTATION (2022)

Article Biophysics

Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis

Joseph E. Maakaron, Mei-Jie Zhang, Karen Chen, Sunil Abhyankar, Vijaya Raj Bhatt, Saurabh Chhabra, Najla El Jurdi, Sherif S. Farag, Fiona He, Mark Juckett, Marcos de Lima, Navneet Majhail, Marjolein van der Poel, Ayman Saad, Bipin Savani, Celalettin Ustun, Edmund K. Waller, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Wael Saber, Daniel Weisdorf

Summary: A study on 1321 AML patients aged 60 and older found that age alone is not a barrier to successful HCT in CR1, and efforts should focus on minimizing residual disease and better donor selection.

BONE MARROW TRANSPLANTATION (2022)

Letter Biophysics

Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant

Pranay S. Hegde, Lisa Rybicki, Sheila Serafino, Laura Bernhard, Donna Corrigan, Faiz Anwer, Matt Kalaycio, Ronald M. Sobecks, Deepa Jagadeesh, Brian T. Hill, Robert M. Dean, Jack Khouri, Allison M. Winter, Brad Pohlman, Navneet S. Majhail, Betty K. Hamilton

BONE MARROW TRANSPLANTATION (2022)

Letter Biophysics

Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel

Agrima Mian, Wei Wei, Betty K. Hamilton, Allison M. Winter, Jack Khouri, Brad Pohlman, Aaron T. Gerds, Deepa Jagadeesh, Faiz Anwer, Matt Kalaycio, Robert M. Dean, Ronald Sobecks, Paolo F. Caimi, Brian T. Hill, Navneet S. Majhail

BONE MARROW TRANSPLANTATION (2023)

Article Health Care Sciences & Services

A Conceptual Framework for Optimizing the Equity of Hospital-Based Emergency Care: The Structure of Hospital Transfer Networks

Charleen Hsuan, Brendan G. Carr, David Vanness, Yinan Wang, Douglas L. Leslie, Eleanor Dunham, Jeannette A. Rogowski

Summary: Current payment policies neglect hospital transfers for emergency conditions, worsening disparities. There is no existing framework that provides a patient-centered, population-based perspective for the structure of hospital transfer networks. The hospital transfer network equity-quality model highlights the factors that determine the structure of hospital transfer networks, including structural inequity and racism.

MILBANK QUARTERLY (2023)

Article Hematology

Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, Marcos de Lima, Shahrukh Hashmi, Mohamed A. Kharfan-Dabaja, Navneet S. Majhail, Rahul Banerjee, Ayman Saad, Gerhard C. Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J. Lekakis, Sagar S. Patel, Hemant S. Murthy, Yago Nieto, Christopher Strouse, Sherif M. Badawy, Samer Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H. Vesole, Cindy H. Lee, Attaphol Pawarode, Usama Gergis, Kevin C. Miller, Leona A. Holmberg, Aimaz Afrough, Melhem Solh, Pashna N. Munshi, Taiga Nishihori, Larry D. Anderson Jr, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H. Qazilbash, Nina Shah, Shaji K. Kumar, Saad Z. Usmani

Summary: The use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT), has significantly improved the overall survival (OS) in multiple myeloma (MM) patients. However, the use of lenalidomide maintenance after auto-HSCT has been associated with an increased risk of second primary malignancies (SPM) and second hematological malignancies (SHM). This study evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in MM patients after auto-HSCT using registry data.

BLOOD ADVANCES (2023)

Article Psychology, Multidisciplinary

A Posterior Expected Value Approach to Decision-Making in the Multiphase Optimization Strategy for Intervention Science

Jillian C. Strayhorn, Linda M. Collins, David J. Vanness

Summary: In the current practice of intervention science, a component screening approach (CSA) is widely used for selecting intervention components based on estimated main effects and interactions. However, we propose an alternative posterior expected value approach based on Bayesian decision theory, which offers easier application and greater flexibility in intervention optimization. Through Monte Carlo simulations, we found that both the posterior expected value approach and CSA outperformed random component selection and classical treatment package approaches. The posterior expected value approach showed slightly more consistent and accurate results compared to CSA across a range of simulated optimization trials, indicating its potential for decision-making in the multiphase optimization strategy (MOST).

PSYCHOLOGICAL METHODS (2023)

Article Surgery

Reassessing surgical guidelines for papillary thyroid cancer impact on survival: Expanding indications for lobectomy

Audrey Stevens, Jennie Meier, Archana Bhat, Sara J. Knight, David J. Vanness, Courtney Balentine

Summary: This study compared survival outcomes between lobectomy and total thyroidectomy in patients with papillary thyroid cancer, while addressing the bias from unmeasured confounding variables. The results showed no significant differences in overall survival or survival in subgroup analyses, indicating that total thyroidectomy does not offer a survival advantage over lobectomy regardless of tumor size, patient age, or overall risk of death.

SURGERY (2023)

Article Hematology

Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships

Rahul Banerjee, Amar H. Kelkar, Urshila Durani, Theodora Anagnostou, Miki Nishitani, Kanwaldeep Mallhi, Navneet S. Majhail, Aaron C. Logan

Summary: Recent guidelines from the American Society for Transplantation and Cellular Therapy have aimed to establish expectations for participants in blood and marrow transplantation (BMT) and cellular therapy (CT) fellowships. A survey was conducted to examine the demographics, motivations, and experiences of recent participants in BMT/CT fellowships. The results showed that the fellowship training had a positive impact on participants' comfort with BMT/CT management and the majority would highly recommend this training to others.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease

Sagar S. Patel, Sanghee Hong, Lisa Rybicki, Stephanie Farlow, Jane Dabney, Matt Kalaycio, Ronald Sobecks, Navneet S. Majhail, Betty K. Hamilton

Summary: Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic cell transplantation (HCT), causing significant physical and psychosocial symptoms. This pilot study aimed to assess the feasibility of using patient-reported outcome (PRO) measures to evaluate symptom burden and quality of life (QOL) in acute GVHD. The study utilized surveys from various PRO measures and found that patients with acute GVHD had lower QOL scores compared to those without or with mild GVHD. The PRO-CTCAE captured several common symptoms of acute GVHD. Challenges in implementing PRO measures in acute GVHD were identified. Further research is needed to make PROs feasible in this patient population.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Rajshekhar Chakraborty, Jean Yi, Lisa Rybicki, Jaime Preussler, Abhinav Deol, Alison Loren, Bipin Savani, Heather S. L. Jim, Jan Cerny, Jana Reynolds, Jennifer Whitten, John R. Wingard, Joseph P. McGuirk, Joseph Uberti, Nandita Khera, Patrick Stiff, Samantha M. Jaglowski, Shahrukh Hashmi, Shernan G. Holtan, Steven Devine, Theresa Hahn, Victoria L. Whalen, Wael Saber, William Wood, K. Scott Baker, Karen Syrjala, Navneet S. Majhail

Summary: Survivors of autologous hematopoietic cell transplantation (AHCT) for multiple myeloma in stable remission do not have clinically meaningful worsening in physical functioning compared to the general population. However, they may experience distress related to health burden, uncertainty, and finances. Adherence to preventive care guidelines is high, but adherence to exercise and diet guidelines is relatively low.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

Abraham S. Kanate, Navneet Majhail, Zachariah Defilipp, Binod Dhakal, Bhagirathbhai Dholaria, Betty Hamilton, Alex F. Herrera, Yoshihiro Inamoto, Tania Jain, Miguel -Angel Perales, Paul A. Carpenter, Mehdi Hamadani

Summary: The American Society for Transplantation and Cellular Therapy (ASTCT) has published guidelines on CAR-T therapy indications, categorizing them as standard of care and recommending only FDA-approved indications. These guidelines will be periodically updated based on new evidence.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Sanghee Hong, Lisa Rybicki, Linda Mclellan, Jane Dabney, Aaron T. Gerds, Seth J. Rotz, Matt Kalaycio, Rabi Hanna, Betty K. Hamilton, Navneet S. Majhail, Ronald M. Sobecks

Summary: This study compared the HRQOL between haplo-HCT and other donor sources for HCT, showing no difference in some aspects but differences in specific situations. Haplo-HCT demonstrated better emotional and functional well-being in certain conditions.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

No Data Available